Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alexion switches to solar power

This article was originally published in Scrip

Executive Summary

Alexion Pharmaceuticals has strengthened its green credentials by putting solar panels generating 295kW on the rooftop of its facility in Cheshire, Connecticut, which will provide 9% of its electrical needs. The system was funded by a grant from the Connecticut Clean Energy Fund. The 1,738 photovoltaic cells will reduce its carbon dioxide emissions by 380,000 lbs annually, the company estimates. Alexion markets the appropriately named product Soliris (eculizumab), for the rare and life-threatening blood disorder, paroxysmal nocturnal haemoglobinuria.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts